- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Alnylam and Tenaya Partner in Potential $1B+ Deal to Develop Heart Disease Treatments
The alliance aims to identify new genetic targets for cardiovascular disease therapies.
Published on Mar. 5, 2026
Got story updates? Submit your updates here. ›
Alnylam Pharmaceuticals and Tenaya Therapeutics have formed a strategic partnership to discover and develop new treatments for heart disease. Under the deal, Alnylam will pay Tenaya $10 million upfront and up to $1.13 billion in potential research funding and milestone payments. Tenaya will leverage its target identification and validation platform to find up to 15 gene targets, which Alnylam will then develop and commercialize.
Why it matters
The alliance represents the latest in a string of recent deals and advancements in the cardiovascular disease space, which has seen a resurgence of interest and innovation after being dominated by statins for decades. By combining Tenaya's target discovery capabilities with Alnylam's expertise in RNA interference therapeutics, the partnership aims to uncover new genetic pathways that could lead to transformative heart disease treatments.
The details
Under the terms of the agreement, Tenaya will receive upfront payment and reimbursement for costs incurred during a two-year validation period. Alnylam will then take over development and commercialization of any candidates that emerge from the collaboration. Tenaya's platform will be used to identify up to 15 gene targets that could lead to disease-modifying therapies for cardiovascular diseases, though the specific disease areas were not disclosed.
- The partnership was announced on March 5, 2026.
The players
Alnylam Pharmaceuticals
A leading biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics.
Tenaya Therapeutics
A South San Francisco-based biotech company developing gene therapy and gene editing programs for cardiovascular diseases.
Faraz Ali
CEO of Tenaya Therapeutics.
What they’re saying
“By combining our modality agnostic target identification and validation capabilities with Alnylam's leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease.”
— Faraz Ali, CEO, Tenaya Therapeutics (Tenaya Therapeutics)
The takeaway
This partnership highlights the renewed focus and innovation in the cardiovascular disease space, as companies like Alnylam and Tenaya look to leverage emerging technologies like RNA interference to uncover new genetic targets and develop transformative treatments for heart conditions.
